Israeli generics giant Teva Pharmaceutical Industries (Teva) announced on 3 August 2016 that it had entered into a definitive agreement to buy US generics business Anda from Allergan.
Teva to acquire US-based generics maker Anda
Home/Pharma News | Posted 12/08/2016 0 Post your comment
Anda is the fourth largest distributor of generics in the US. The company distributes generic, brand, specialty and over-the-counter pharmaceutical products from more than 300 manufacturers to retail independent and chain pharmacies, nursing homes, mail order pharmacies, hospitals, clinics and physician offices across the US.
Teva will pay US$500 million for Anda and expects the company to generate more than US$1 billion in third-party net revenue for 2016.
Anda will continue to operate as a stand-alone business and, as part of the deal, Teva will acquire three distribution centres in Olive Branch, Massachusetts; Weston, Florida; and Groveport, Ohio, with a total of over 650 employees.
The move is expected by Sigurdur Olafsson, President & CEO of Global Generic Medicines, to enable Teva ‘to improve capabilities and flexibility given the changes the pharmaceutical industry is currently undergoing, in order to provide access to more patients throughout the country’.
Related article
Teva and Takeda establish ‘Teva Takeda Yakuhin’ in Japan
Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.
Copyright – Unless otherwise stated all contents of this website are © 2016 Pro Pharma Communications International. All Rights Reserved.
Source: Teva
Guidelines
Regulatory update for post-registration of biological products in Brazil
New regulations in Brazil for the registration of biosimilars
Policies & Legislation
NPRA Malaysia trials new timelines for variation applications
Regulatory evolution and impact of simplified requirements for interchangeable biosimilars in the US
Most viewed articles
The best selling biotechnology drugs of 2008: the next biosimilars targets
Global biosimilars guideline development – EGA’s perspective
Related content
Meitheal expands portfolio with three biosimilars through exclusive US licensing agreement
EMS proposes merger with Hypera to form Brazil's largest drugmaker
Bio-Thera and Gedeon Richter partner to commercialize Stelara biosimilar BAT2206
Advances for Biocon Biologics’ Stelara and Eylea biosimilars
Comments (0)
Post your comment